1
|
Batheja S, Gupta S, Tejavath KK, Gupta U. TPP-based conjugates: potential targeting ligands. Drug Discov Today 2024; 29:103983. [PMID: 38641237 DOI: 10.1016/j.drudis.2024.103983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Revised: 03/30/2024] [Accepted: 04/10/2024] [Indexed: 04/21/2024]
Abstract
Mitochondria are one of the major sources of energy as well as regulators of cancer cell metabolism. Thus, they are potential targets for the effective treatment and management of cancer. Research has explored triphenylphosphonium (TPP) derivatives as potent cancer-targeting ligands because of their lipophilic nature and mitochondrial affinity. In this review, we summarize the utility of TPP-based conjugates targeting mitochondria in different types of cancer and other diseases, such as neurodegenerative and cardiovascular disorders. Such conjugates offer versatile therapeutic potential by modulating membrane potential, influencing reactive oxygen species (ROS) production, and coupling of molecular modifications (such as ATP metabolism and energy metabolism). Thus, we highlight TPP conjugates as promising mitochondria-targeting agents for use in targeted drug delivery systems.
Collapse
Affiliation(s)
- Sanya Batheja
- Nanopolymeric Drug Delivery Lab, Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, Ajmer 305817, India
| | - Shruti Gupta
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, Ajmer 305817, India
| | - Kiran Kumar Tejavath
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, Ajmer 305817, India; Department of Biochemistry, All India Institute of Medical Sciences, BIBINAGAR, Hyderabad Metropolitan Region (HMR), Telangana 508126, India.
| | - Umesh Gupta
- Nanopolymeric Drug Delivery Lab, Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, Ajmer 305817, India.
| |
Collapse
|
2
|
Valderrama V, Sánchez P, Delso M, Díaz-Dosque M, Escobar A, Budini M, Catalán M, Vivar R, López-Muñoz R, Jara JA, Molina-Berríos A. Gallic acid triphenylphosphonium derivatives TPP+-C10 and TPP+-C12 inhibit mitochondrial function in Candida albicans exerting antifungal and antibiofilm effects. J Appl Microbiol 2024; 135:lxad316. [PMID: 38148145 DOI: 10.1093/jambio/lxad316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 11/20/2023] [Accepted: 12/25/2023] [Indexed: 12/28/2023]
Abstract
AIMS To evaluate the antifungal and antibiofilm activity of gallic acid derivatives TPP+-C10 and TPP+-C12 and their effects on mitochondrial function on two Candida albicans reference strains (ATCC 90029 and ATCC 10231). METHODS AND RESULTS First, we determined minimal inhibitory concentration (MIC) using a microdilution assay. Both compounds exerted antifungal effects, and their MICs ranged from 3.9 to 13 µM, with no statistically significant differences between them (P > 0.05, t-test). These concentrations served as references for following assays. Subsequently, we measured oxygen consumption with a Clark electrode. Our observations revealed that both drugs inhibited oxygen consumption in both strains with TPP+-C12 exerting a more pronounced inhibitory effect. We then employed flow cytometry with TMRE as a probe to assess mitochondrial membrane potential. For each strain assayed, the compounds induced a decay in transmembrane potential by 75%-90% compared to the control condition (P < 0.05, ANOVA). Then, we measured ATP levels using a commercial kit. TPP+-C12 showed a 50% decrease of ATP content (P < 0.05 ANOVA), while TPP+-C10 exhibited a less pronounced effect. Finally, we assessed the antibiofilm effect using the MTT reduction assay. Both compounds were effective, but TPP+-C12 displayed a greater potency, requiring a lower concentration to inhibit 50% of biofilms viability (P < 0.05, t-test). CONCLUSIONS Derivatives of gallic acid linked to a TPP+ group exert antifungal and antibiofilm activity through impairment of mitochondrial function in C. albicans.
Collapse
Affiliation(s)
- Victoria Valderrama
- Laboratory of Applied Pharmacology for the Development of Anticancer and Antifungal Drugs, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| | - Paula Sánchez
- Laboratory of Applied Pharmacology for the Development of Anticancer and Antifungal Drugs, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| | - Macarena Delso
- Laboratory of Applied Pharmacology for the Development of Anticancer and Antifungal Drugs, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| | - Mario Díaz-Dosque
- Laboratory of Applied Pharmacology for the Development of Anticancer and Antifungal Drugs, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
- Laboratory of Nanobiomaterials, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| | - Alejandro Escobar
- Laboratory of Cellular Biology, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| | - Mauricio Budini
- Cellular and Molecular Pathology Laboratory, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| | - Mabel Catalán
- Clinical and Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Santiago, 8380453, Chile
| | - Raúl Vivar
- Clinical and Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Santiago, 8380453, Chile
| | - Rodrigo López-Muñoz
- Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia, 5110566, Chile
| | - José A Jara
- Laboratory of Applied Pharmacology for the Development of Anticancer and Antifungal Drugs, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| | - Alfredo Molina-Berríos
- Laboratory of Applied Pharmacology for the Development of Anticancer and Antifungal Drugs, Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, University of Chile, Santiago, 8380544, Chile
| |
Collapse
|
3
|
Çetin F, Kosba S, Abdik H, Bolat ZB. Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells. Med Oncol 2023; 41:11. [PMID: 38071672 DOI: 10.1007/s12032-023-02239-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Accepted: 11/06/2023] [Indexed: 12/18/2023]
Abstract
Neuroblastoma, a tumor of the sympathetic nervous system, is one of the most common tumors found in children. Most patients develop resistance to therapy and show poor prognosis, thus there is a need of novel therapeutic agents for the treatment of neuroblastoma. NVP-BEZ235 is a dual Phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor that induces apoptosis and suppresses the growth of cancer. Curcumin acts as an anticancer agent in certain cancers. This study investigated the synergetic effect of NVP-BEZ235 and curcumin against neuroblastoma SH-SY5Y cell line. In the current study, the synergic effect of NVP-BEZ235 and curcumin in SH-SY5Y was examined in terms of the cell growth by cell viability and colony forming assay, cell cycle and apoptotic cell death by flow cytometry and mRNA expression levels by quantitative Real Time Polymerase Chain Reaction (qRT-PCR). Curcumin, NVP-BEZ235 or a combination of both, showed cytotoxicity in a dose and time dependent manner in SH-SY5Y cells. 10 µM curcumin and 200 nM NVP-BEZ235 were chosen as combination therapy, as the combination index showed synergism. Colony forming assay showed decrease in cell growth in combination group. The cell cycle distribution for combination group demonstrated a decrease in G0/G1 phase at 48 h. Annexin V showed an anticancer effect in combination group when compared to control group. Moreover, qRT-PCR results showed a significant increase in caspase 3, caspase 7, Bax and p53 genes, while a decrease in Bcl-2 gene expression levels. These findings suggest that combination therapy of NVP-BEZ235 and curcumin may be a promising therapeutic candidate for treatment of neuroblastoma.
Collapse
Affiliation(s)
- Fadime Çetin
- Sabri Ulker R&D Center, Istanbul Sabahattin Zaim University, Kucukcekmece, Istanbul, Turkey
| | - Sifa Kosba
- Sabri Ulker R&D Center, Istanbul Sabahattin Zaim University, Kucukcekmece, Istanbul, Turkey
| | - Hüseyin Abdik
- Sabri Ulker R&D Center, Istanbul Sabahattin Zaim University, Kucukcekmece, Istanbul, Turkey
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Sabahattin Zaim University, Kucukcekmece, Istanbul, 34303, Turkey
| | - Zeynep Busra Bolat
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Sabahattin Zaim University, Kucukcekmece, Istanbul, 34303, Turkey.
- Molecular Biology and Genetics Department, Hamidiye Institute of Health Sciences, University of Health Sciences- Turkey, Istanbul, 34668, Turkey.
- Experimental Medicine Research and Application Center, Validebag Research Park, University of Health Sciences, Uskudar, Istanbul, 34662, Turkey.
| |
Collapse
|
4
|
Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy. Cancers (Basel) 2023; 15:cancers15030666. [PMID: 36765624 PMCID: PMC9913854 DOI: 10.3390/cancers15030666] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 01/15/2023] [Accepted: 01/19/2023] [Indexed: 01/25/2023] Open
Abstract
Cancer is one of the leading causes of death and the most important impediments to the efforts to increase life expectancy worldwide. Currently, chemotherapy is the main treatment for cancer, but it is often accompanied by side effects that affect normal tissues and organs. The search for new alternatives to chemotherapy has been a hot research topic in the field of antineoplastic medicine. Drugs targeting diseased tissues or cells can significantly improve the efficacy of drugs. Therefore, organelle-targeted antitumor drugs are being explored, such as mitochondria-targeted antitumor drugs. Mitochondria is the central site of cellular energy production and plays an important role in cell survival and death. Moreover, a large number of studies have shown a close association between mitochondrial metabolism and tumorigenesis and progression, making mitochondria a promising new target for cancer therapy. Combining mitochondrial targeting agents with drug molecules is an effective way of mitochondrial targeting. In addition, hyperpolarized tumor cell membranes and mitochondrial membrane potentially allow selective accumulation of mitochondria-targeted drugs. This enhances the direct killing of tumor cells by drug molecules while minimizing the potential toxicity to normal cells. In this review, we discuss the common pro-mitochondrial agents, the advantages of triphenylphosphine (TPP) in mitochondrial-targeted cancer therapy and systematically summarize various TPP-based mitochondria-targeting anticancer drugs.
Collapse
|
5
|
de Freitas Domingues JS, Dos Santos SMD, das Neves Rodrigues Ferreira J, Monti BM, Baggio DF, Hummig W, Araya EI, de Paula E, Chichorro JG, Ferreira LEN. Antinociceptive effects of bupivacaine and its sulfobutylether-β-cyclodextrin inclusion complex in orofacial pain. Naunyn Schmiedebergs Arch Pharmacol 2022; 395:1405-1417. [PMID: 35909169 DOI: 10.1007/s00210-022-02278-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Accepted: 07/23/2022] [Indexed: 10/16/2022]
Abstract
Bupivacaine hydrochloride (BVC) represents an option to produce long-lasting analgesia, and complexation in cyclodextrins has shown improvements in biopharmaceutical properties. This study aimed to characterize and test the cytotoxicity and antinociceptive effects of BVC complexed in sulfobutylether-β-cyclodextrin (SBEβCD). The kinetics and stoichiometry of complexation and BVC-SBEβCD association constant were evaluated by phase solubility study and Job's plot. Evidence of the BVC-SBEβCD complex formation was obtained from scanning electron microscopy (SEM), infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC). The cytotoxicity was evaluated in keratinocyte (HaCaT) and neuroblastoma (SH-SY5Y). Antinociceptive effects were registered via orofacial pain models: the formalin test, carrageenan-induced hyperalgesia, and postoperative pain (intraoral incision). The complex formation occurred at a 1:1 BVC-SBEβCD molar ratio, with a low association constant (13.2 M-1). SEM, DSC, and FTIR results demonstrated the host-guest interaction. The IC50% values determined in SH-SY5Y were 216 µM and 149 µM for BVC and BVC-SBEβCD, respectively (p < 0.05). There was no difference in HaCaT IC50%. In orofacial pain model, BVC-SBEβCD significantly prolonged antinociceptive effect, in about 2 h, compared to plain BVC. SBEβCD can be used as a drug delivery system for bupivacaine, whereas the complex showed long-lasting analgesic effects.
Collapse
Affiliation(s)
| | | | | | - Bianca Miguel Monti
- Laboratory of Inflammation and Immunology, Guarulhos University, Guarulhos, São Paulo, Brazil
| | - Darciane Favero Baggio
- Department of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Parana, Brazil
| | - Wagner Hummig
- Department of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Parana, Brazil
| | - Erika Ivanna Araya
- Department of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Parana, Brazil
| | - Eneida de Paula
- Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, Sao Paulo, Brazil
| | - Juliana Geremias Chichorro
- Department of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Parana, Brazil
| | | |
Collapse
|
6
|
Calixto GMF, Muniz BV, Castro SR, de Araujo JSM, de Souza Amorim K, Ribeiro LNM, Ferreira LEN, de Araújo DR, de Paula E, Franz-Montan M. Mucoadhesive, Thermoreversible Hydrogel, Containing Tetracaine-Loaded Nanostructured Lipid Carriers for Topical, Intranasal Needle-Free Anesthesia. Pharmaceutics 2021; 13:1760. [PMID: 34834175 PMCID: PMC8617820 DOI: 10.3390/pharmaceutics13111760] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 10/01/2021] [Accepted: 10/13/2021] [Indexed: 12/04/2022] Open
Abstract
Recent advances have been reported for needle-free local anesthesia in maxillary teeth by administering a nasal spray of tetracaine (TTC) and oxymetazoline, without causing pain, fear, and stress. This work aimed to assess whether a TTC-loaded hybrid system could reduce cytotoxicity, promote sustained permeation, and increase the anesthetic efficacy of TTC for safe, effective, painless, and prolonged analgesia of the maxillary teeth in dental procedures. The hybrid system based on TTC (4%) encapsulated in nanostructured lipid carriers (NLC) and incorporated into a thermoreversible hydrogel of poloxamer 407 (TTCNLC-HG4%) displayed desirable rheological, mechanical, and mucoadhesive properties for topical application in the nasal cavity. Compared to control formulations, the use of TTCNLC-HG4% slowed in vitro permeation of the anesthetic across the nasal mucosa, maintained cytotoxicity against neuroblastoma cells, and provided a three-fold increase in analgesia duration, as observed using the tail-flick test in mice. The results obtained here open up perspectives for future clinical evaluation of the thermoreversible hybrid hydrogel, which contains TTC-loaded NLC, with the aim of creating an effective, topical, intranasal, needle-free anesthesia for use in dentistry.
Collapse
Affiliation(s)
- Giovana Maria Fioramonti Calixto
- Department of Biosciences, Piracicaba Dental School, University of Campinas-UNICAMP, Piracicaba 13414-903, Brazil; (G.M.F.C.); (B.V.M.); (J.S.M.d.A.); (K.d.S.A.)
| | - Bruno Vilela Muniz
- Department of Biosciences, Piracicaba Dental School, University of Campinas-UNICAMP, Piracicaba 13414-903, Brazil; (G.M.F.C.); (B.V.M.); (J.S.M.d.A.); (K.d.S.A.)
| | - Simone R. Castro
- Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-872, Brazil; (S.R.C.); (E.d.P.)
| | - Jaiza Samara Macena de Araujo
- Department of Biosciences, Piracicaba Dental School, University of Campinas-UNICAMP, Piracicaba 13414-903, Brazil; (G.M.F.C.); (B.V.M.); (J.S.M.d.A.); (K.d.S.A.)
| | - Klinger de Souza Amorim
- Department of Biosciences, Piracicaba Dental School, University of Campinas-UNICAMP, Piracicaba 13414-903, Brazil; (G.M.F.C.); (B.V.M.); (J.S.M.d.A.); (K.d.S.A.)
| | - Lígia N. M. Ribeiro
- Institute of Biotechnology, Federal University of Uberlandia-UFU, Uberlandia 38405-302, Brazil;
| | | | | | - Eneida de Paula
- Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-872, Brazil; (S.R.C.); (E.d.P.)
| | - Michelle Franz-Montan
- Department of Biosciences, Piracicaba Dental School, University of Campinas-UNICAMP, Piracicaba 13414-903, Brazil; (G.M.F.C.); (B.V.M.); (J.S.M.d.A.); (K.d.S.A.)
| |
Collapse
|
7
|
Shrestha R, Johnson E, Byrne FL. Exploring the therapeutic potential of mitochondrial uncouplers in cancer. Mol Metab 2021; 51:101222. [PMID: 33781939 PMCID: PMC8129951 DOI: 10.1016/j.molmet.2021.101222] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 03/17/2021] [Accepted: 03/23/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Mitochondrial uncouplers are well-known for their ability to treat a myriad of metabolic diseases, including obesity and fatty liver diseases. However, for many years now, mitochondrial uncouplers have also been evaluated in diverse models of cancer in vitro and in vivo. Furthermore, some mitochondrial uncouplers are now in clinical trials for cancer, although none have yet been approved for the treatment of cancer. SCOPE OF REVIEW In this review we summarise published studies in which mitochondrial uncouplers have been investigated as an anti-cancer therapy in preclinical models. In many cases, mitochondrial uncouplers show strong anti-cancer effects both as single agents, and in combination therapies, and some are more toxic to cancer cells than normal cells. Furthermore, the mitochondrial uncoupling mechanism of action in cancer cells has been described in detail, with consistencies and inconsistencies between different structural classes of uncouplers. For example, many mitochondrial uncouplers decrease ATP levels and disrupt key metabolic signalling pathways such as AMPK/mTOR but have different effects on reactive oxygen species (ROS) production. Many of these effects oppose aberrant phenotypes common in cancer cells that ultimately result in cell death. We also highlight several gaps in knowledge that need to be addressed before we have a clear direction and strategy for applying mitochondrial uncouplers as anti-cancer agents. MAJOR CONCLUSIONS There is a large body of evidence supporting the therapeutic use of mitochondrial uncouplers to treat cancer. However, the long-term safety of some uncouplers remains in question and it will be critical to identify which patients and cancer types would benefit most from these agents.
Collapse
Affiliation(s)
- Riya Shrestha
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, 2052, Australia
| | - Edward Johnson
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, 2052, Australia
| | - Frances L Byrne
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, 2052, Australia.
| |
Collapse
|
8
|
Catalán M, Olmedo I, Faúndez J, Jara JA. Medicinal Chemistry Targeting Mitochondria: From New Vehicles and Pharmacophore Groups to Old Drugs with Mitochondrial Activity. Int J Mol Sci 2020; 21:E8684. [PMID: 33217901 PMCID: PMC7698797 DOI: 10.3390/ijms21228684] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 11/10/2020] [Accepted: 11/12/2020] [Indexed: 12/11/2022] Open
Abstract
Interest in tumor cell mitochondria as a pharmacological target has been rekindled in recent years. This attention is due in part to new publications documenting heterogenous characteristics of solid tumors, including anoxic and hypoxic zones that foster cellular populations with differentiating metabolic characteristics. These populations include tumor-initiating or cancer stem cells, which have a strong capacity to adapt to reduced oxygen availability, switching rapidly between glycolysis and oxidative phosphorylation as sources of energy and metabolites. Additionally, this cell subpopulation shows high chemo- and radioresistance and a high capacity for tumor repopulation. Interestingly, it has been shown that inhibiting mitochondrial function in tumor cells affects glycolysis pathways, cell bioenergy, and cell viability. Therefore, mitochondrial inhibition may be a viable strategy for eradicating cancer stem cells. In this context, medicinal chemistry research over the last decade has synthesized and characterized "vehicles" capable of transporting novel or existing pharmacophores to mitochondrial tumor cells, based on mechanisms that exploit the physicochemical properties of the vehicles and the inherent properties of the mitochondria. The pharmacophores, some of which have been isolated from plants and others, which were synthesized in the lab, are diverse in chemical nature. Some of these molecules are active, while others are prodrugs that have been evaluated alone or linked to mitochondria-targeted agents. Finally, researchers have recently described drugs with well-proven safety and efficacy that may exert a mitochondria-specific inhibitory effect in tumor cells through noncanonical mechanisms. The effectiveness of these molecules may be improved by linking them to mitochondrial carrier molecules. These promising pharmacological agents should be evaluated alone and in combination with classic chemotherapeutic drugs in clinical studies.
Collapse
Affiliation(s)
- Mabel Catalán
- Clinical and Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile, Independencia 1027, Santiago 8380453, Chile;
| | - Ivonne Olmedo
- Physiopathology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile, Independencia 1027, Santiago 8380453, Chile;
| | - Jennifer Faúndez
- Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, Universidad de Chile, Olivos 943, Santiago 8380544, Chile;
| | - José A. Jara
- Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, Universidad de Chile, Olivos 943, Santiago 8380544, Chile;
| |
Collapse
|
9
|
Catalán M, Castro-Castillo V, Gajardo-de la Fuente J, Aguilera J, Ferreira J, Ramires-Fernandez R, Olmedo I, Molina-Berríos A, Palominos C, Valencia M, Domínguez M, Souto JA, Jara JA. Continuous flow synthesis of lipophilic cations derived from benzoic acid as new cytotoxic chemical entities in human head and neck carcinoma cell lines. RSC Med Chem 2020; 11:1210-1225. [PMID: 33479625 DOI: 10.1039/d0md00153h] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 07/30/2020] [Indexed: 01/17/2023] Open
Abstract
Continuous flow chemistry was used for the synthesis of a series of delocalized lipophilic triphenylphosphonium cations (DLCs) linked by means of an ester functional group to several hydroxylated benzoic acid derivatives and evaluated in terms of both reaction time and selectivity. The synthesized compounds showed cytotoxic activity and selectivity in head and neck tumor cell lines. The mechanism of action of the molecules involved a mitochondrial uncoupling effect and a decrease in both intracellular ATP production and apoptosis induction.
Collapse
Affiliation(s)
- Mabel Catalán
- Clinical and Molecular Pharmacology Program , Institute of Biomedical Sciences (ICBM) , Faculty of Medicine , Universidad de Chile , Santiago , 8380453 , Chile
| | - Vicente Castro-Castillo
- Department of Organic and Physical Chemistry , Faculty of Chemical and Pharmaceutical Sciences , Universidad de Chile , Santos Dumont 964 , Santiago 8380494 , Chile
| | - Javier Gajardo-de la Fuente
- Department of Organic and Physical Chemistry , Faculty of Chemical and Pharmaceutical Sciences , Universidad de Chile , Santos Dumont 964 , Santiago 8380494 , Chile
| | - Jocelyn Aguilera
- Institute for Research in Dental Sciences (ICOD) , Faculty of Dentistry , Universidad de Chile , Santiago , 8380492 , Chile . ; Tel: +56 2 29781730
| | - Jorge Ferreira
- Clinical and Molecular Pharmacology Program , Institute of Biomedical Sciences (ICBM) , Faculty of Medicine , Universidad de Chile , Santiago , 8380453 , Chile
| | | | - Ivonne Olmedo
- Physiopathology Program , Institute of Biomedical Sciences (ICBM) , Faculty of Medicine , Universidad de Chile , Santiago 8380453 , Chile
| | - Alfredo Molina-Berríos
- Institute for Research in Dental Sciences (ICOD) , Faculty of Dentistry , Universidad de Chile , Santiago , 8380492 , Chile . ; Tel: +56 2 29781730
| | - Charlotte Palominos
- Clinical and Molecular Pharmacology Program , Institute of Biomedical Sciences (ICBM) , Faculty of Medicine , Universidad de Chile , Santiago , 8380453 , Chile
| | - Marcelo Valencia
- Clinical and Molecular Pharmacology Program , Institute of Biomedical Sciences (ICBM) , Faculty of Medicine , Universidad de Chile , Santiago , 8380453 , Chile
| | - Marta Domínguez
- Departamento de Química Orgánica , Facultad de Química , CINBIO and IIS Galicia Sur , Universidade de Vigo , E-36310 , Vigo , Spain .
| | - José A Souto
- Departamento de Química Orgánica , Facultad de Química , CINBIO and IIS Galicia Sur , Universidade de Vigo , E-36310 , Vigo , Spain .
| | - José A Jara
- Institute for Research in Dental Sciences (ICOD) , Faculty of Dentistry , Universidad de Chile , Santiago , 8380492 , Chile . ; Tel: +56 2 29781730
| |
Collapse
|